REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Chemistry: Natural Resins Or Derivatives; Peptides Or Proteins; Lignins Or Reaction Products Thereof > Proteins, I.e., More Than 100 Amino Acid Residues > Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc.Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010662 - Vgf fusion polypeptides The present invention provides novel VGF polypeptides and selective binding agents. The invention also provides host cells and methods for producing VGF polypeptides. The invention further provides VGF pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, conditions, and disorders associated with VGF polypeptides. ... 12/28/06 - 20060293507 - Crystallization of igf-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method ... 12/21/06 - 20060287510 - Crystallization of igf-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method ... 12/14/06 - 20060281905 - Crystallization of igf-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method ... 12/07/06 - 20060276634 - Peg-conjugated erythropoietin The present invention provides a polyethylene glycol-conjugated erythropoietin (PEG-conjugated EPO) prepared by PEG conjugation on the lysine residue at position 52 of native erythropoietin (native EPO). In order to achieve more sustained efficacy without losing physiological activities of native EPO, a glycoprotein rich in sugar chains, there has been a ... 11/30/06 - 20060270839 - Crystallization of igf-1 Crystalline IGF-1 is provided along with a method for production thereof. Crystallizing IGF-1 comprises the steps of mixing an aqueous solution comprising IGF-1 with a reservoir solution comprising a precipitant to form a mixture; and crystallizing the mixture, optionally also recrystallizing and isolating the crystalline IGF-1. In addition, a method ... 11/30/06 - 20060270838 - Pantropic neurotrophic factors Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided. ... 11/09/06 - 20060252919 - Vegf variant that lacks vegfr-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis A VEGF145 polypeptide devoid of a VEGFR-1 binding activity and methods of making and using same in preventing and/or treating restenosis are provided. ... 07/13/06 - 20060155117 - Novel preadipocyte factor-1-like polypeptides The present invention discloses open reading frames (ORFs) in human genome encoding for novel Preadipocyte factor-1-like polypeptides, and reagents related thereto including variants, mutants and fragments of said polypeptides, as well as ligands and antagonists directed against them. The invention provides methods for identifying and making these molecules, for preparing ... 06/22/06 - 20060135754 - Novel carbamylated epo and method for its production The present invention discloses a method for production of novel carbamylated erythropoietin and compositions comprising the novel carbamylated erythropoietin and pharmaceutical compositions comprising this and uses thereof. ... 06/15/06 - 20060128947 - Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor Compositions are described that are suitable for formulating TFPI. Solubilizers and stabilizers facilitate the preparation of pharmaceutically acceptable compositions of TFPI at various concentrations. ... 05/04/06 - 20060094865 - Intraoperative method for isolating and concentrating autologous growth factors and for forming residual autologous growth factor compositions This invention is concerned with methods and devices for isolation or concentration of autologous growth factors; particularly autologous growth factors derived from blood or bone marrow or other bodily fluid/cell compositions in an intraoperative manner. Additionally, this invention provides specifically tailored growth factor residual compositions resulting from removal of one ... 04/06/06 - 20060074230 - Chimeric coiled coil molecules The present application describes a fusion molecule that includes coiled coil domain, which renders the molecule soluble and provides potent activity. ... 03/23/06 - 20060063922 - Epidermal differentiation factor A human epidermal differentiation factor polypeptide and DNA (RNA) encoding such polypeptide and procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating and/or preventing skin diseases. Diagnostic assays for detecting mutations in a nucleic acid sequence encoding a polypeptide ... 02/02/06 - 20060025577 - Endothelial cell growth factor methods of isolation and expression A novel growth factor specific for vascular endothelial cells has been identified in conditioned medium of bovine pituitary derived folliculo stellate cells. This factor, named folliculo stellate derived growth facto (FSdGF) or vascular endothelial growth factor (VEGF), was purified to homogeneity by a combination of heparin sepharose affinity chromatography, Bio ... 01/05/06 - 20060004189 - Compositions for treating wounds and processes for their preparation The present invention provides a process for obtaining growth factors by treating a growth factor starting material to release growth factors from the growth factor starting material and recovering growth factors from the treated growth factor starting material. The growth factor obtained can be used in compositions to treat humans. ... 11/10/05 - 20050250936 - Modified tgf-beta superfamily proteins The invention provides modified TGF-β family proteins having altered biological or biochemical properties, and methods for making them. Specific modified protein constructs include TGF-β family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers. ... 10/06/05 - 20050222394 - Dual chain synthetic heparin-binding growth factor analogs The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and ... 07/07/05 - 20050148763 - Peg-binding pth or peg-binding pth derivative The object of the present invention is to provide PTH or a PTH derivative, which is modified to attain increased bioavailability without losing PTH activity and to have a reduced risk of side effects. PEG conjugation to PTH or a PTH derivative increases the bioavailability while maintaining PTH activity and ... ### FreshPatents.com Support |